SymBio pharma - TREAKISYM’s Label Expansion + Rigosertib’s Potential in MDS market + Cash to In-license More!
SymBio (4582) licensed Onconova’s Rigosertib (SyB L-1101, PhI, RRMDS, Dual inhibitor of PI-3 and PL-1 Kinase Inhibitor) and gained Japan/Korea rights in 2011. Onconova Therapeutics (ONTX) debut in NASDAQ has been very encouraging and should percolate into SymBio especially in light of the upcoming PhIII data in US of Rigosertib IV (Rig. IV) in RRMDS by YE13. Disappointing guidance of TREAKISYM (bendamustine hydrochloride, L, rrNHL, MCL) sales for FY13 (¥1,563m, lowered down by ~¥365m) hit the stock, but future potential of its product portfolio remains intact with... For more detail please read our report on SymBio released on 3rd Sept. 2013, titled, "TREAKISYM’s Label Expansion + Rigosertib’s Potential in MDS market + Cash to In-license More!"
More Publications
SYMBIO - Growth Driver: PI3K Inhibitor’s Rigosertib & Cash to In-license More!
US$ 140.00
February 2013
4 pages
SYMBIO - Significant Upside still Remains: Bendamustine + Regosertib + Cash to In-license More!
US$ 90.00
January 2013
5 pages
Celgene (CELG) - Label Expansion of Marketed Product and Newly Drug launches + Maturing Pipeline = Long Term Gain
US$ 140.00
September 2013
6 pages
ALEXION - Great Expectations From Label Expansion
US$ 140.00
September 2011
4 pages
ALEXION: Soliris’ Label Expansion & Diversification to Perk ALXN Up!
US$ 140.00
April 2012
5 pages
